Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Allen C, Barber RM, et al.Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol, 2017. 3(4): 524–548
   PubMed Web of Science ®Google Scholar
• Oronsky B, Reid TR, Oronsky A, et al. What’s new in SCLC? A review. Neoplasia. 2017;19(10):842–847.
   PubMed Web of Science ®Google Scholar
• Wang SC, Tang JJ, Sun TT, et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Sci Rep. 2017;7(1):1339.
   PubMedGoogle Scholar
• Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121(5):664–672.
   PubMed Web of Science ®Google Scholar
• Pietanza MC, Byers LA, Minna JD, et al. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res. 2015;21(10):2244–2255.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline. J Clin Oncol. 2015;33(34):4106–4111.
   PubMed Web of Science ®Google Scholar
• Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018;7(1):69–79.
   PubMed Web of Science ®Google Scholar
• Stahel R, Thatcher N, Früh M, et al. 1st ESMO consensus conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann Oncol. 2011;22(9):1973–1980.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009;27(28):4787–4792.
   PubMed Web of Science ®Google Scholar
• Rossi A, Maio MD, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–1698.
   PubMed Web of Science ®Google Scholar
• Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052–1062.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen YB, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939.
   PubMed Web of Science ®Google Scholar
• Guidelines Working Committee of Chinese society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology (CSCO) small-cell lung cancer. Beijing: People’s Medical Publishing House; 2020.
   Google Scholar
• Zhou KX, Zhou J, Huang JX, et al. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung Cancer. 2019;130:1–4.
   PubMed Web of Science ®Google Scholar
• Li LY, Wang H, Chen X, et al. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China. Chin Med J (Engl). 2019;132(23):2790–2794.
   PubMed Web of Science ®Google Scholar
• Roth JA, Yuan Y, Othus M, et al. A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer. J Med Econ. 2021;24(1):79–86.
   PubMed Web of Science ®Google Scholar
• Zhou K, Wen F, Zhang P, et al. Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial. Clin Transl Oncol. 2018;20(6):768–774.
   PubMed Web of Science ®Google Scholar
• Hartwell D, Jones J, Loveman E, et al. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer Treat Rev. 2011;37(3):242–249.
   PubMed Web of Science ®Google Scholar
• Task group of the Chinese guidelines for pharmacoeconomic evaluations, Liu GE, Hu SL, et al.China guidelines for pharmacoeconomic evaluations. China J Pharm Econ, 2011, 6: 7–48
   Google Scholar
• Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–528.
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
   PubMed Web of Science ®Google Scholar
• Djalalov S, Beca J, Ewara EM, et al. A comparison of different analysis methods for reconstructed survival data to inform cost‑effectiveness analysis. Pharmacoeconomics. 2019;37(12):1525–1536.
   PubMed Web of Science ®Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139.
   PubMed Web of Science ®Google Scholar
• Wan XM, Peng LB, Li YJ. A review and comparison of methods for recreating individual patient data from published Kaplan-Meier survival curves for economic evaluations: a simulation study. PloS One. 2015;10(3):e0121353.
   PubMed Web of Science ®Google Scholar
• Li HC, Lai L, Wu B. Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Clin Drug Invest. 2020;40(2):183–189.
   PubMed Web of Science ®Google Scholar
• Gu XH, Zhang Q, Chu YB, et al. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer. 2019;127:84–89.
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84.
   PubMed Web of Science ®Google Scholar
• Chinese Medical Association. Oncology Society of Medical Association, Chinese Medical Association publishing house, Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (2019 edition). Chin J Oncol. 2020;42(4):257–287.
   Google Scholar
• Zhu J, He W, Ye M, et al. Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. Future Oncol. 2018;14(27):2833–2840.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EAL, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32(5):722–732.
   PubMed Web of Science ®Google Scholar